Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01875796 |
Recruitment Status
:
Completed
First Posted
: June 12, 2013
Last Update Posted
: August 25, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cannabis Dependence Anxiety Disorders Cannabis Use Disorder Cannabis Abuse | Behavioral: Cognitive-Behavioral Therapy Behavioral: Motivation Enhancement Therapy Behavioral: Integrated Cannabis and Anxiety Reduction Treatment Behavioral: False Safety Behavior Elimination Therapy | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 68 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders |
Study Start Date : | June 2013 |
Actual Primary Completion Date : | July 2016 |
Arm | Intervention/treatment |
---|---|
Experimental: Cannabis & Anxiety Reduction Treatment
Cognitive-behavioral treatment program that integrates strategies to manage both cannabis use and anxiety with techniques to address motivation to change cannabis use.
|
Behavioral: Cognitive-Behavioral Therapy
Behavioral: Motivation Enhancement Therapy
Behavioral: Integrated Cannabis and Anxiety Reduction Treatment
Behavioral: False Safety Behavior Elimination Therapy
Other Name: Transdiagnostic anxiety disorder treatment
|
Active Comparator: Motivation/cognitive-behavioral therapy
Motivational Enhancement Therapy (MET) and cognitive-behavioral therapy (CBT) that includes techniques to address motivation to change cannabis use with strategies to manage use.
|
Behavioral: Cognitive-Behavioral Therapy Behavioral: Motivation Enhancement Therapy |
- cannabis use [ Time Frame: change from baseline to weeks 6, 12, & 32 ]
- cannabis-related problems [ Time Frame: change from baseline to weeks 6, 12, & 32 ]
- anxiety [ Time Frame: change from baseline to weeks 6, 12, & 32 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of cannabis use disorder
- An additional diagnosis of an anxiety disorder
- Patient reports that at least some of his/her cannabis use is aimed at reducing anxiety and/or for social facilitation.
- Patient reports that cannabis is his/her substance of choice for anxiety management.
- Concurrent use of psychotropic medications (e.g., selective serotonin reuptake inhibitors) is permitted as long as patients have been on a stable dose for at least three months prior to entering the study and they are willing to remain stable on their medication for the duration of treatment.
- Age between 18 and 65 years.
- English language fluency.
- Willing and able to provide written informed consent.
Exclusion Criteria:
- Alcohol or illicit substance (non-cannabis) dependence.
- Cannabis use behavior sufficiently uncontrolled that proper participation in study protocol would likely be disrupted.
- History of schizophrenia, bipolar disorder, or organic brain syndrome.
- Prominent suicidal ideation with intent that is judged to be clinically significant.
- Mental retardation or another pervasive developmental disability (e.g., Asperger's Disorder).
- Sufficiently socially unstable as to preclude completion of study requirements (e.g., homeless).
- Prior simultaneous cognitive behavioral treatment for cannabis dependence and anxiety disorders.
- Legally mandated to receive substance abuse treatment.
- Report of current participation in or intent to participate in an additional (i.e., treatments other than MET-CBT or MET alone) anxiety or substance abuse treatment method during the course of the study.
- Unwilling to maintain stable dose of regularly-dosed medications during the study
- Unwilling to cease PRN (pro re nata or "as needed") use of benzodiazepines or other fast-acting anxiolytics prior to entrance into social situations.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01875796
United States, Louisiana | |
Louisiana State University Anxiety & Addictive Behaviors Clinic | |
Baton Rouge, Louisiana, United States, 70803 |
Principal Investigator: | Julia D Buckner, PhD | Louisiana State University Health Sciences Center in New Orleans | |
Principal Investigator: | Michael J Zvolensky, PhD | University of Houston |
Additional Information:
Responsible Party: | Julia Buckner, Associate Professor, Louisiana State University and A&M College |
ClinicalTrials.gov Identifier: | NCT01875796 History of Changes |
Other Study ID Numbers: |
RDA031937A 1R34DA031937-01 ( U.S. NIH Grant/Contract ) |
First Posted: | June 12, 2013 Key Record Dates |
Last Update Posted: | August 25, 2016 |
Last Verified: | August 2016 |
Keywords provided by Julia Buckner, Louisiana State University and A&M College:
cannabis marijuana anxiety transdiagnostic |
dual diagnosis cannabis abuse cannabis dependence cannabis use disorder |
Additional relevant MeSH terms:
Disease Anxiety Disorders Marijuana Abuse Pathologic Processes |
Mental Disorders Substance-Related Disorders Chemically-Induced Disorders |